Clinuvel granted Australian formulation patent
Filed with ASX ·
Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Clinuvel Pharmaceuticals Limited on 6ix
Earlier from Clinuvel Pharmaceuticals
- Response to ASX price query
- Observations from Clinuvel`s programs being presented at AAD
- Clinuvel - positive results from pivotal Phase III EPP study
- Clinuvel granted US topical formulation patent
- Clinuvel files European MAA for SCENESSE (afamelanotide)
Later from Clinuvel Pharmaceuticals
- Clinuvel reports positive results in Phase III EPP trial
- Clinuvel selects leading US manufacturing partner
- Clinuvel - strategic focus of final regulatory program
- Clinuvel to evaluate SCENESSE as therapy in vitiligo
- Patent to assist drug as potential skin cancer preventative
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals